Reply to the letter to the editor 'Anti-EGFR therapy in oesophagogastric cancer: precise but not enough' by M. Salati and S. Cascinu

Ann Oncol. 2018 Sep 1;29(9):2018. doi: 10.1093/annonc/mdy238.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Cetuximab
  • Chemoradiotherapy
  • ErbB Receptors
  • Esophageal Neoplasms*
  • Humans
  • Neoadjuvant Therapy*


  • EGFR protein, human
  • ErbB Receptors
  • Cetuximab